Ferinject® approved in Chinafor the treatment of iron deficiency in adult patients
View the full release here: https://www.businesswire.com/news/home/20221127005020/en/
- View the full release here: https://www.businesswire.com/news/home/20221127005020/en/
CSL Vifor and Fresenius Kabi today announced that Chinas National Medical Products Administration (NMPA) has approved Ferinject, a preparation for intravenous iron therapy for the treatment of iron deficiency in adult patients for whom oral iron preparations are ineffective, oral iron preparations cannot be used or for whom there is a clinical need to deliver iron rapidly. - We are thrilled about the marketing authorization of Ferinject, which is a milestone for Chinese patients living with iron deficiency or iron deficiency anemia, said Herv Gisserot, General Manager of CSL Vifor.
- There is a high unmet need in China, which has the worlds largest iron deficiency population, and we are confident that Ferinject can make a meaningful difference in the treatment of these patients.
- This open label, randomized multicenter study showed that Ferinject is an effective and well-tolerated alternative to iron sucrose for the treatment of iron deficiency anemia that can provide an improved hemoglobin response and correction of iron deficiency in Chinese patients.